Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3

2(28.6%)

Phase 2

2(28.6%)

N/A

1(14.3%)

Phase 1

1(14.3%)

Phase 4

1(14.3%)

7Total

Phase 3(2)

Phase 2(2)

N/A(1)

Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07486830Phase 2Recruiting

IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction

Role: collaborator

NCT04075981Phase 3Recruiting

Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)

Role: collaborator

NCT02577224Not ApplicableCompleted

An RCT of a Patient-initiated Treatment Service for BEB and HFS

Role: collaborator

NCT04792398Phase 4Unknown

Bruxism Xeomin® Intervention Trial

Role: collaborator

NCT01565395Phase 2Withdrawn

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

Role: collaborator

NCT01405482Phase 1Unknown

Botulinum Toxin Injections for Thoracic Outlet Syndrome

Role: collaborator

NCT00909883Phase 3Unknown

Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)

Role: collaborator

All 7 trials loaded